FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.

Abstract excerpt

The FMS-like receptor tyrosine kinase-3 (FLT3) plays a key role in hematopoietic development and is frequently mutated in patients with acute myeloid leukemia (AML). These mutations render FLT3 constitutively active, and patients harboring these mutations have a poor prognosis. Targeting the kinase activity of FLT3 with inhibitory compounds is therefore an attractive therapeutic option. Over the last few years,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Disease Models, Animal
• Share to fms-Like Tyrosine Kinase 3